Spravato faces ongoing legal challenges, primarily concerning its patent protection and market exclusivity [1]. Litigation often targets the validity of existing patents or alleges anticompetitive practices related to its market entry [1][2].
What is Spravato's active ingredient and its medical use?
Spravato is the brand name for esketamine, a nasal spray medication approved for treating treatment-resistant depression and depressive symptoms in adults with major depressive disorder [3][4]. It is a derivative of ketamine and works by targeting the glutamate system in the brain [4].
When does Spravato's patent protection expire?
The patent landscape for Spravato is complex and subject to ongoing legal disputes. Specific patent expiry dates can be affected by litigation outcomes [1]. Information on the exact expiration of relevant patents can be found on resources like DrugPatentWatch.com [1].
Who is challenging Spravato's patents?
Generic drug manufacturers are typically the entities challenging patents for branded drugs like Spravato. These challenges aim to pave the way for the introduction of lower-cost generic versions once patents are deemed invalid or expire [1][2].
What are the primary arguments in Spravato lawsuits?
Lawsuits involving Spravato often center on patent infringement claims, where generic manufacturers may argue that their proposed products do not infringe existing patents. Another common area of litigation involves allegations that the patent holder engaged in "evergreening" or other tactics to unfairly extend market exclusivity beyond what is intended by patent law [1][2].
How does Spravato compare to other depression treatments?
Spravato represents a newer class of antidepressants that act more rapidly than traditional selective serotonin reuptake inhibitors (SSRIs). Unlike SSRIs, which take weeks to show effects, Spravato can provide relief within days for some patients [3][4]. However, it requires administration in a certified medical facility due to potential side effects and monitoring needs [4].
What are the potential risks and side effects associated with Spravato?
Spravato carries significant risks, including serious side effects such as sedation, dissociation, and abuse potential [3][4]. Patients are monitored for at least two hours after administration due to these risks. It is also associated with a potential for increased blood pressure [3].
Can biosimilar or generic versions of Spravato be developed?
The development of generic esketamine nasal spray is contingent on the outcome of patent litigation and the eventual expiry of patent and other forms of exclusivity [1][2]. Generic manufacturers are actively seeking to enter the market with their versions of the drug [2].